Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human DEP-SN38 in advanced solid tumours
ISRCTN99654100Phase 2Completed
- Sponsor
- Starpharma
- Start
- Sep 2019
- Modality
- Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
01
Overview
Phase 2, open-label trial of DEP-SN38 in Nonhematologic neoplasms (2 arms), sponsored by Starpharma. Primary endpoints: Maximum tolerated dose and Dose-limiting toxicities. Started Sep 2019; status: completed.
02
Drugs
DEP-SN38
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on ISRCTN99654100.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN99654100.